97271 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments
Sub-classes:ORTHOGONAL MUTATIONS FOR HETERODIMERIZATION
#2Engineered Heterodimeric Proteins
#3Antibodies to Amyloid Beta
#4Pharmaceutical Composition For Treating Or Preventing At Least One Disease Selected From Group Consisting Of Inflammatory Bowel Disease And Intestinal Tumor
#5HUMAN LAMBDA LIGHT CHAIN MICE
#6SERUM ALBUMIN BINDERS
#7ANTI-FLT-1 ANTIBODIES FOR TREATING DUCHENNE MUSCULAR DYSTROPHY
#8BISPECIFIC ANTIBODY TREATMENT OF LYMPHOID MALIGNANT NEOPLASM CONDITIONS
#9NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE
#10ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGEN AND THEIR METHODS OF USE
#11ENGINEERED HETERODIMERIC PROTEINS
#12Microvascular endothelial cell comprising a nucleic acid encoding an anti-TDP-43 fab
#13Orthogonal mutations for heterodimerization
#14METHODS AND FORMULATIONS FOR REDUCING RECONSTITUTION TIME OF LYOPHILIZED POLYPEPTIDES
#15Anti-PACAP antibodies and uses thereof
#16Anti-LAG3 antibodies and antigen-binding fragments
#17MICE THAT MAKE HEAVY CHAIN ANTIBODIES
#18SYSTEM AND METHOD FOR CHARACTERIZING DRUG PRODUCT IMPURITIES
#19METHODS OF PRODUCING TWO CHAIN PROTEINS IN BACTERIA
#20Activatable Anti-CTLA-4 Antibodies and Uses Thereof
#21Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
#22CHIMERIC ANTIGEN RECEPTORS COMPRISING BCMA-SPECIFIC FIBRONECTIN TYPE III DOMAINS AND USES THEREOF
#23Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
#24Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion
#25Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders
#26Methods of treatment with anti-PACAP antibodies
#27Anti-TrkB agonist antibodies binding to D1 domain of TrkB
#28MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME
#29ANTIBODIES THAT BIND EBOLA GLYCOPROTEIN AND USES THEREOF
#30RECOMBINANT SINGLE CHAIN IMMUNOGLOBULINS
#31Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
#32Natriuretic peptide receptor 1 antibodies and methods of use
#33Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis
#34HUMAN LAMBDA LIGHT CHAIN MICE
#35Humanized antibodies binding to amyloid-beta (A-beta)
#36Ultralong complementarity determining regions and uses thereof
#37Anti-PACAP antibodies
#38Anti-PACAP antibodies
#39Hetero-Dimeric Immunoglobulins
#40Anti-TrkB agonist antibodies binding to D5 domain of TrkB and methods of promoting neuronal survival in motor neuron injury, stroke or glaucoma
#41MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE
#42Methods and formulations for reducing reconstitution time of lyophilized polypeptides
#43MODIFIED CK AND CH1 DOMAINS
#44Engineered heterodimeric proteins
#45Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin
#46Activatable anti-CTLA-4 antibodies and uses thereof
#47Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody
#48Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof
#49Antibody-drug conjugate having cyclic benzylidene acetal linker
#50Immunoglobulin constant region Fc receptor binding agents
#51HUMAN LAMBDA LIGHT CHAIN MICE
#52Methods for modifying human antibodies by glycan engineering
#53HUMAN LAMBDA LIGHT CHAIN MICE
#54Method of producing antibody fragment
#55Anti-LAG3 antibodies and antigen-binding fragments
#56Methods of producing two chain proteins in bacteria
#57Anti-LAG3 antibodies and antigen-binding fragments
#58Anti-LAG3 antibodies and antigen-binding fragments
#59ANTI-NGF ANTIBODIES AND THEIR USE
#60COMPOSITIONS AND METHODS FOR TREATING CANCER
#61METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE, FOR ACTIVATING ANTIGEN PRESENTING CELLS
#62Immunoglobulin constant region Fc receptor binding agents
#63IMMUNOGLOBULIN GLYCOSYLATION PATTERN ANALYSIS
#64RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
#65RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
#66Hetero-Dimeric Immunoglobulins
#67Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
#68Trispecific binding molecules for treating HBV infection and associated conditions
#69Anti-Flt-1 antibodies for treating duchenne muscular dystrophy
#70Human lambda light chain mice
#71IL-17 antibody formulations and methods of treatment using same
#72Multispecific antibodies facilitating selective light chain pairing
#73Liquid formulation of long acting insulinotropic peptide conjugate
#74IMMUNOGLOBULINS WITH REDUCED AGGREGATION
#75COMPOSITIONS AND METHODS FOR TREATING CANCER
#76Antibodies that bind Ebola glycoprotein and uses thereof
#77Antibody-drug conjugate having cyclic benzylidene acetal linker
#78ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
#79Anti-LAG3 antibodies and antigen-binding fragments
#80ANTIBODIES AGAINST NERVE GROWTH FACTOR (NGF) WITH ENHANCED IN VIVO STABILITY
#81Immunoglobulin constant region Fc receptor binding agents
#82Method for the purification of antibodies
#83Methods of preventing inflammation and treating pain using anti-NGF compositions
#84Human lambda light chain mice
#85Immunoglobulin constant region Fc receptor binding agents
#86Recombinant production of mixtures of antibodies
#87IL-17 antibody formulations and methods of treatment using same
#88Anti-NGF antibodies and their use
#89Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
#90Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to G protein-coupled receptor 49 (GPR49)
#91Methods of producing two chain proteins in bacteria
#92Human antibodies binding to RSV G proteins
#93Human antibodies binding to RSV G protein
#94Human lambda light chain mice
#95Human lambda light chain mice
#96B7-H4 fusion proteins and methods of use thereof
#97Caninized anti-NGF antibodies and their use
#98Humanized Anti-Factor D Antibodies And Uses Thereof
#99Hybrid light chain mice
#100Mice that make heavy chain antibodies
#101Method of cloning a lambda light chain variable domain using a human lambda light chain mouse
#102Method of making antibodies using a human lambda light chain mouse
#103Method of making antibodies using a human lambda light chain mouse
#104COMPOSITIONS AND METHODS FOR TREATING CANCER
#105Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK
#106Readily isolated bispecific binding molecules with native format having mutated constant regions
#107Human lambda light chain mice
#108Multispecific antibodies, multispecific activatable antibodies and methods of using the same
#109Immunoglobulin constant region Fc receptor binding agents
#110Methods related to TIM 3, a Th1-specific cell surface molecule, for activating antigen presenting cells
#111Methods related to TIM 3, a TH1-specific cell surface molecule, for activating antigen presenting cells
#112Lysosome-cleavable linker
#113Methods of inhibiting solid tumor growth by administering GPR49 antibodies
#114Chemical Modification of Antibodies
#115IL-17 antibody formulation and method of treatment using same
#116IL-17 binding proteins
#117IL-17 binding proteins
#118Immunoglobulins with reduced aggregation
#119IL-17 binding proteins
#120Mice that make heavy chain antibodies
#121Method for the purification of antibodies
#122Hetero-dimeric immunoglobulins
#123Immunoglobulin constant region FC receptor binding agents
#124Ultralong complementarity determining regions and uses thereof
#125Hetero-dimeric immunoglobulins
#126Methods of preventing inflammation and treating pain using anti-NGF compositions
#127Anti-NGF antibodies and their use
#128Human lambda light chain mice
#129Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
#130Immunoglobulin cleavage fragments and disease indicators and compositions for detecting and binding such
#131Methods related to TIM 3, a Th1-specific cell surface molecule, for activating antigen presenting cells
#132IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
#133MULTISPECIFIC MODULAR ANTIBODY
#134B7-H4 fusion proteins and methods of use thereof
#135IMMUNOGLOBULIN CLEAVAGE FRAGMENT VACCINE COMPOSITIONS
#136Chromatography purification of antibodies
#137COMPOSITIONS AND METHODS OF MONOCLONAL AND POLYCLONAL ANTIBODIES SPECIFIC FOR T CELL SUBPOPULATIONS
#138Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
#139Humanized anti-factor D antibodies and uses thereof
#140Methods and compositions for the inhibition of transplant rejection
#141Humanized anti-CD47 antibody
#142B cell surface reactive antibodies
#143Hybrid light chain mice
#144Human lambda light chain mice
#145Immunoglobulins with reduced aggregation
#146IMMUNOGLOBULIN GLYCOSYLATION PATTERN ANALYSIS
#147IMMUNOGLOBULINS DEVOID OF LIGHT CHAINS
#148Group A Streptococcus Pharmaceutical Compositions and Methods Thereof
#149Recombinant production of mixtures of antibodies
#150CD37 immunotherapeutics and uses thereof
#151Nucleic acids encoding anti-factor D antibodies
#152Mice that make heavy chain antibodies
#153METHODS FOR SYSTEMATIC CONTROL OF PROTEIN STABILITY
#154Proteolysis Resistant Antibody Preparations
#155Methods of treating with anti-factor D antibodies
#156Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
#157NEOPLASM SPECIFIC ANTIBODIES AND USES THEREOF
#158Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
#159IL-17 binding proteins
#160Modulating immune responses
#161Immunoglobulin constant region FC receptor binding agents
#162ANTI-MICROBIAL TARGETING CHIMERIC PHARMACEUTICAL
#163HUMAN EPO RECEPTOR AGONISTS, COMPOSITIONS, METHODS AND USES FOR PREVENTING OR TREATING GLUCOSE INTOLERANCE RELATED CONDITIONS
#164H-Chain-only antibodies
#165CONSTRUCTS AND LIBRARIES COMPRISING ANTIBODY SURROGATE KAPPA LIGHT CHAIN SEQUENCES
#166CHIMERIC NON-HUMAN ANIMAL
#167Benzoimidazole compounds
#168Benzoimidazole compounds
#169CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
#170Benzoimidazole compounds
#171Benzoimidazole compounds
#172Chromatography purification of antibodies
#173Benzoimidazole compounds
#174Benzoimidazole compounds
#175Benzoimidazole compounds
#176Benzoimidazole compounds
#177Recombinant production of mixtures of antibodies
#178Altered polypeptides, immunoconjugates thereof, and methods related thereto
#179Benzoimidazole Compounds
#180Aptameric IgE peptides in a protein scaffold as an allergy vaccine
#181Immunoglobulin Cleavage Fragments as Disease Indicators and Compositions for Detecting and Binding Such
#182Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
#183Method for the Purification of Antibodies
#184THERAPEUTIC DRUG FOR HEART DISEASE AND VIRUS DISEASE
#185Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
#186Engineered plasmids and their use for in situ production of genes
#187Antibodies to CD83
#188Humanized anti-factor D antibodies
#189Humanized anti-CD47 antibody
#190Neoplasm specific antibodies and uses thereof
#191Immunoglobulins devoid of light chains
#192Production of Proteins Carrying Oligomannose or Human-Like Glycans in Yeast and Methods of Use Thereof
#193Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
#194Prevention of brain inflammation as a result of induced autoimmune response
#195Method for the recombinant expression of a polypeptide
#196Recombinant production of mixtures of antibodies
#197Immunoglobulins devoid of light chains
#198Recombinant production of mixtures of antibodies
#199Proteolysis resistant antibody preparations
#200Specificity exchangers that redirect antibodies to a pathogen
#201Method for screening a library of VHH polypeptides
#202Single chain antibody with cleavable linker
#203Heterodimeric protein binding compositions
#204Anti-pci neutralizing antibody
#205IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
#206Immunoglobulins devoid of light chains
#207Hinge core mimetibodies, compositions, methods and uses
#208Immunoglobulins devoid of light chains
#209Specificity exchangers that redirect antibodies to a pathogen
#210Neoplasm specific antibodies and uses thereof
#211Synthetic peptides that bind to the hepatitis B virus core and E antigens
#212Prevention of brain inflammation as a result of induced autoimmune response
#213Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease
#214Means and methods for manipulating hypersensitivity-like responses
#215Chimeric nonhuman animal
#216Recombinant production of mixtures of antibodies
#217Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
#218Benzoimidazole compounds
#219Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses